In the News

Share

Connect with us

Stay Informed.

Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
COVID-19: Information for Patients and Caregivers

We're here for you, and continue to provide cancer care to new and current patients. Learn about our response to COVID-19.

What you need to know

1666 News Items found
Melanie Steele, MPH, Director of Patient Financial Engagement at PFS
Making Cancer Treatment More Affordable: MSK Nurses Ensuring Access to Care

Memorial Sloan Kettering Cancer Center (MSK) is committed not only to providing exceptional cancer care but also to ensuring access to care for everyone who needs it. Unfortunately, some patients — often those whose insurance plan offers a very narrow provider network or those who are underinsured — have trouble shouldering the significant financial burden that can come with a cancer diagnosis. MSK has a special team in place to make sure these patients can still get the care they deserve.
A scientist holds a box of frozen samples
MSK Research Highlights, February 23, 2023

New research from MSK offers a window into patients’ complex decision-making around adjuvant therapy, explores the promise of engineered CAR T cells, highlights the success of a summer research program to support groups underrepresented in science, and more.
Q&A
Dr. Sergio Giralt
Improving Treatment for Recurrent Multiple Myeloma With Ide-Cel CAR T Therapy

In this Q&A, MSK hematologic oncologist Sergio Giralt, MD, talks about a phase 3 trial of ide-cel CAR T therapy for people with recurrent multiple myeloma and what it may mean for people with this hard-to-treat blood cancer.
woman getting vaccine from doctor
HPV Vaccine Age Limit: You Might Not Be Too Old — What You Should Know

Learn from MSK experts what people over 26 should know about getting the HPV vaccine to protect themselves from several forms of cancer.
Tobias M. Hohl, MD, PhD
Tobias M. Hohl Elected a 2022 AAAS Fellow

Tobias M. Hohl, MD, PhD, Chief of the Infectious Diseases Service in the Department of Medicine, was elected a 2022 Fellow of the American Association for the Advancement of Science (AAAS), the world’s largest scientific society and publisher of the Science journals. This title is one of the most distinguished honors within the scientific community and is designed to recognize leaders for their notable contributions to science.
Patient Mary Oehrlein at her Long Island home near MSK Commack, where a diagnostic biopsy test identified the best treatment for her pancreatic cancer
Start Your Cancer Treatment Fast With MSK's Rapid Diagnosis

The day before Thanksgiving, Mary Oehrlein got the earth-shattering news. She’d had some tests at her local hospital to see what was causing her stomach problems. When she got a message to check her patient portal for results, she was stunned to read the words “possible pancreatic cancer.” She went to tell Rich, her husband of 53 years, and they cried.
Dr. Selwyn Vickers seen outdoors with his wife, Janice, and their four children.
Black History Seen Through the Remarkable Family of Dr. Selwyn Vickers

Experience a remarkable portrait of Black history in America through the family story of Dr. Selwyn Vickers, the President and CEO of Memorial Sloan Kettering Cancer Center.
Feature
Robin Bankins
FDA Approves First Treatment for Patients With All Forms of Histiocytosis

Based a clinical trial conducted at MSK, the FDA has approved the targeted drug cobimetinib (Cotellic®) for treating a rare group of diseases known as histiocytoses, or histiocytic neoplasms in adults.
MSK multiple myeloma specialist Sham Mailankody
Off-the-Shelf CAR T Cell Therapy for Multiple Myeloma Shows Promise

A new type of CAR T cell therapy for multiple myeloma could shorten the time to treatment.
detail shot of a scientist pipetting in a lab
MSK Research Highlights, January 20, 2023

New research from MSK explores novel predictors of immunotherapy effectiveness against lung cancer; identifies how a high-fat diet hinders intestinal damage repair; reports findings from a clinical trial for people with androgen receptor-positive salivary gland cancer; and aims to understand the impact of tumor mutational burden on patients with locally advanced non-small cell lung cancer.